Lilit Karapetyan

1.0k total citations · 2 hit papers
35 papers, 542 citations indexed

About

Lilit Karapetyan is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Lilit Karapetyan has authored 35 papers receiving a total of 542 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Oncology, 13 papers in Immunology and 8 papers in Molecular Biology. Recurrent topics in Lilit Karapetyan's work include Cancer Immunotherapy and Biomarkers (12 papers), CAR-T cell therapy research (10 papers) and Immunotherapy and Immune Responses (9 papers). Lilit Karapetyan is often cited by papers focused on Cancer Immunotherapy and Biomarkers (12 papers), CAR-T cell therapy research (10 papers) and Immunotherapy and Immune Responses (9 papers). Lilit Karapetyan collaborates with scholars based in United States, Jordan and China. Lilit Karapetyan's co-authors include John M. Kirkwood, Andrew Knight, Jason J. Luke, Diwakar Davar, Dario A.A. Vignali, Anthony R. Cillo, Creg J. Workman, Lawrence P. Andrews, Cindy Sander and Arivarasan Karunamurthy and has published in prestigious journals such as Cell, Journal of Clinical Investigation and Journal of Clinical Oncology.

In The Last Decade

Lilit Karapetyan

34 papers receiving 534 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Immunotherapy in Melanoma: Recent Advances and Future Directions

2023 125 citations Andrew Knight, Lilit Karapetyan et al. Cancers profile →
Blockade of LAG-3 and PD-1 leads to co-expression of cytotoxic and exhaustion gene modules in CD8+ T cells to promote antitumor immunity

2024 75 citations Anthony R. Cillo, Carly Cardello et al. Cell profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Lilit Karapetyan United States	10	326	258	133	83	37	35	542
Jaspreet Singh Grewal United States	12	354 1.1×	168 0.7×	153 1.2×	84 1.0×	50 1.4×	46	654
Luisa Chocarro Spain	14	504 1.5×	362 1.4×	134 1.0×	111 1.3×	45 1.2×	35	742
Lingdi Zhao China	15	319 1.0×	167 0.6×	125 0.9×	140 1.7×	62 1.7×	55	518
Naoshi Kawamura Japan	10	233 0.7×	204 0.8×	156 1.2×	46 0.6×	57 1.5×	12	456
Xinxin Zhu China	13	387 1.2×	242 0.9×	157 1.2×	144 1.7×	111 3.0×	19	650
Charlée Nardin France	12	245 0.8×	198 0.8×	296 2.2×	89 1.1×	78 2.1×	55	584
Lena Horvath Austria	8	281 0.9×	167 0.6×	157 1.2×	134 1.6×	92 2.5×	17	456
Clara Chong Hui Ong Singapore	11	281 0.9×	204 0.8×	162 1.2×	64 0.8×	89 2.4×	19	498
Hans Anton Schloesser Germany	5	247 0.8×	168 0.7×	136 1.0×	89 1.1×	54 1.5×	11	438
Chikara Takahashi United States	8	324 1.0×	568 2.2×	153 1.2×	39 0.5×	39 1.1×	13	779

Countries citing papers authored by Lilit Karapetyan

Since Specialization

Citations

This map shows the geographic impact of Lilit Karapetyan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lilit Karapetyan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lilit Karapetyan more than expected).

Fields of papers citing papers by Lilit Karapetyan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lilit Karapetyan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lilit Karapetyan. The network helps show where Lilit Karapetyan may publish in the future.

Co-authorship network of co-authors of Lilit Karapetyan

This figure shows the co-authorship network connecting the top 25 collaborators of Lilit Karapetyan. A scholar is included among the top collaborators of Lilit Karapetyan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lilit Karapetyan. Lilit Karapetyan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Khushalani, Nikhil I., Ghassan El‐Haddad, Kenneth L. Gage, et al.. (2024). First-in-human study of ²²⁵actinium mti-201 (²²⁵Ac-MTI-201) in metastatic uveal melanoma (UM).. Journal of Clinical Oncology. 42(16_suppl). TPS9612–TPS9612. 1 indexed citations

Khushalani, Nikhil I., Ghassan El‐Haddad, Kenneth L. Gage, et al.. (2024). 1128P Preliminary results of first-in-human study of 225-Actinium MTI-201 (225Ac-MTI-201) in metastatic uveal melanoma. Annals of Oncology. 35. S742–S742. 1 indexed citations

Eroglu, Zeynep, Joseph Markowitz, Lilit Karapetyan, et al.. (2024). Durability of immune checkpoint inhibitor (ICI) response following treatment discontinuation in advanced merkel cell carcinoma (MCC).. Journal of Clinical Oncology. 42(16_suppl). 9596–9596.

Perez, Matthew, et al.. (2024). Combination Atezolizumab, Cobimetinib, and Vemurafenib as a Treatment Option in BRAF V600 Mutation–Positive Melanoma: Patient Selection and Perspectives. Cancer Management and Research. Volume 16. 933–939. 1 indexed citations

Eroglu, Zeynep, Joseph Markowitz, Lilit Karapetyan, et al.. (2024). Durability of response to immune checkpoint blockade following treatment discontinuation and efficacy of rechallenge in advanced Merkel cell carcinoma. Journal for ImmunoTherapy of Cancer. 12(9). e009816–e009816. 5 indexed citations

Cillo, Anthony R., Carly Cardello, Feng Shan, et al.. (2024). Blockade of LAG-3 and PD-1 leads to co-expression of cytotoxic and exhaustion gene modules in CD8+ T cells to promote antitumor immunity. Cell. 187(16). 4373–4388.e15. 75 indexed citations breakdown →

Karapetyan, Lilit, Andrew Knight, Hong Wang, et al.. (2024). Differences in the pathological, transcriptomic, and prognostic implications of lymphoid structures between primary and metastatic cutaneous melanomas. Journal for ImmunoTherapy of Cancer. 12(11). e009231–e009231. 5 indexed citations

Perez, Matthew, et al.. (2024). Management of acral lentiginous melanoma: current updates and future directions. Frontiers in Oncology. 14. 1323933–1323933. 9 indexed citations

Filderman, J, Jennifer L. Taylor, Jianmin Wang, et al.. (2024). Antagonism of regulatory ISGs enhances the anti-melanoma efficacy of STING agonists. Frontiers in Immunology. 15. 2 indexed citations

10.

Perez, Matthew, Jane L. Messina, Lilit Karapetyan, Rogerio I. Neves, & Vernon K. Sondak. (2023). Acral melanoma: clinical advances and hope for the future.. PubMed. 21(8). 400–409. 3 indexed citations

11.

Knight, Andrew, Lilit Karapetyan, & John M. Kirkwood. (2023). Immunotherapy in Melanoma: Recent Advances and Future Directions. Cancers. 15(4). 1106–1106. 125 indexed citations breakdown →

12.

Karapetyan, Lilit, et al.. (2023). Radiation dose, schedule, and novel systemic targets for radio-immunotherapy combinations. JNCI Journal of the National Cancer Institute. 115(11). 1278–1293. 12 indexed citations

13.

Korpics, Mark, Rebekah Dadey, Lilit Karapetyan, et al.. (2023). Partial tumor irradiation plus pembrolizumab in treating large advanced solid tumor metastases. Journal of Clinical Investigation. 133(10). 19 indexed citations

14.

Andrews, Lawrence P., Anthony R. Cillo, Lilit Karapetyan, et al.. (2022). Molecular Pathways and Mechanisms of LAG3 in Cancer Therapy. Clinical Cancer Research. 28(23). 5030–5039. 71 indexed citations

15.

Karapetyan, Lilit, et al.. (2021). Case Report: Single Dose Anti-PD1 in a Patient With Metastatic Melanoma and Cardiac Allograft. Frontiers in Immunology. 12. 660795–660795. 3 indexed citations

16.

Karapetyan, Lilit, et al.. (2020). Toll-Like Receptor 9 Agonists in Cancer. SHILAP Revista de lepidopterología. 2 indexed citations

17.

Karapetyan, Lilit, Xi Yang, Hong Wang, et al.. (2020). Indoor tanning exposure in association with multiple primary melanoma. Cancer. 127(4). 560–568. 7 indexed citations

18.

Karapetyan, Lilit & John M. Kirkwood. (2020). State of Melanoma. Hematology/Oncology Clinics of North America. 35(1). 1–27. 5 indexed citations

19.

Karapetyan, Lilit, Jason J. Luke, & Diwakar Davar. (2020). <p>Toll-Like Receptor 9 Agonists in Cancer</p>. OncoTargets and Therapy. Volume 13. 10039–10061. 100 indexed citations

20.

Karapetyan, Lilit, et al.. (2018). An overview of the toxicities of checkpoint inhibitors in older patients with cancer. Journal of Geriatric Oncology. 9(5). 451–458. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact